Fate Therapeutics to Present at Upcoming March Investor Conferences
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical firm, will present at two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical firm, will present at two upcoming investor conferences. The events include the 43rd Annual TD Cowen Health Care Conference on March 8, 2023, in Boston and the Barclays Global Healthcare Conference on March 14, 2023, in Miami. Live webcasts of these presentations will be available on the company's website. Fate Therapeutics is focused on developing innovative induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to treat cancer and autoimmune diseases, leveraging its proprietary iPSC product platform.
Details
News Market Reaction – FATE
The recorded move for FATE in the trading session of this news was -4.75%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences:
- 43rd Annual TD Cowen Health Care Conference on Wednesday, March 8, 2023 at 12:50 PM ET in Boston, Massachusetts
- Barclays Global Healthcare Conference on Tuesday, March 14, 2023 at 3:05 PM ET in Miami, Florida
A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at www.fatetherapeutics.com. The archived webcast will be available on the Company’s website shortly after the event.
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Matthew Guido
Stern Investor Relations, Inc.
212.362.1200
matthew.guido@sternir.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.